How much does ibrutinib cost after reimbursement?

Ibrutinib/Ibrutinib, also known as Imbruvica, is mainly used in medicine to treat a variety of blood system diseases, especially chronic lymphocytic leukemia (CLL), mantle cell lymphoma (Mantle Cell Lymphoma, MCL), Waldenström’s Macroglobulinemia (WM) etc. It is a BTK inhibitor that inhibits the growth and spread of tumor cells by blocking the Bruton's Tyrosine Kinase (BTK) signaling pathway.

Ibrutinib is only available by prescription, and treatment should be started and supervised by a doctor experienced in using cancer drugs. Ibrutinib is available in capsule (70 mg, 140 mg) and tablet (140, 280, 420 mg) forms. For patients with MCL, the dose is 560 mg once daily, and for patients with CLL or WM, the usual dose is 420 mg once daily. As long as the condition improves or remains stable and side effects are acceptable, ibrutinib treatment should be continued.

In China, ibrutinib capsules have been included in the national medical insurance catalog. For eligible patients, the treatment costs can be reimbursed through medical insurance. Taking the specifications of 140 mg * 90 capsules as an example, each box may cost more than 10,000 yuan. However, the amount after medical insurance reimbursement will vary based on the patient's actual situation, medical insurance reimbursement ratio, region, drug dosage and course of treatment and other factors.

Generally speaking, after medical insurance reimbursement, the patient's out-of-pocket portion will be greatly reduced, but the exact post-reimbursement price needs to be checked according to the personal medical insurance policy. In order to obtain accurate post-reimbursement prices, it is recommended that patients or family members contact the local medical insurance management department or hospital for consultation. Medical insurance policies may change over time, so check the latest policy information.